T1	p 16 46	epithelial ovarian carcinoma :
T2	p 233 369	patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy . PATIENTS
T3	p 382 434	Patients with measurable and assessable disease were
T4	p 718 752	of 474 patients were treated ( 239
T5	p 814 826	population .
T6	p 1889 1909	patient population .
T7	i 79 129	pegylated liposomal doxorubicin versus topotecan .
T8	i 176 229	pegylated liposomal doxorubicin ( PLD ) and topotecan
T9	i 464 481	PLD 50 mg/m ( 2 )
T10	i 509 510	4
T11	i 517 538	or topotecan 1.5 mg/m
T12	i 765 776	topotecan )
T13	o 153 207	efficacy and safety of pegylated liposomal doxorubicin
T14	o 831 870	overall progression-free survival rates
T15	o 923 967	overall response rates for PLD and topotecan
T16	o 1020 1049	Median overall survival times
T17	o 1210 1235	progression-free survival
T18	o 1317 1339	overall survival , PLD
T19	o 1518 1526	survival
T20	o 1569 1596	Severe hematologic toxicity
T21	o 1670 1739	dosage modification , or growth factor or blood product utilization .
T22	o 1766 1774	efficacy
T23	o 1777 1818	favorable safety profile , and convenient